Cold to Hot: Tumor Immunotherapy by Promoting Vascular Normalization Based on PDGFB Nanocomposites

Immunotherapy is a promising cancer therapeutic strategy. However, the “cold” tumor immune microenvironment (TIME), characterized by insufficient immune cell infiltration and immunosuppressive status, limits the efficacy of immunotherapy. Tumor vascular abnormalities due to defective pericyte coverage are gradually recognized as a profound determinant in “cold” TIME establishment by hindering immune cell trafficking. Recently, several vascular normalization strategies by improving pericyte coverage have been reported, whereas have unsatisfactory efficacy and high rates of resistance. Herein, a combinatorial strategy to induce tumor vasculature‐targeted pericyte recruitment and zinc ion‐mediated immune activation with a platelet‐derived growth factor B (PDGFB)‐loaded, cyclo (Arg‐Gly‐Asp‐D‐Phe‐Lys)‐modified zeolitic imidazolate framework 8 (PDGFB@ZIF8‐RGD) nanoplatform is proposed. PDGFB@ZIF8‐RGD effectively induced tumor vascular normalization, which facilitated trafficking and infiltration of immune effector cells, including natural killer (NK) cells, M1‐like macrophages and CD8+ T cells, into tumor microenvironment. Simultaneously, vascular normalization promoted the accumulation of zinc ions inside tumors to trigger effector cell immune activation and effector molecule production. The synergy between these two effects endowed PDGFB@ZIF8‐RGD with superior capabilities in reprogramming the “cold” TIME to a “hot” TIME, thereby initiating robust antitumor immunity and suppressing tumor growth. This combinatorial strategy for improving immune effector cell infiltration and activation is a promising paradigm for solid tumor immunotherapy. A combinatorial strategy to induce tumor vasculature‐targeted pericyte recruitment and zinc ion‐mediated immune activation with a composite nanoplatform (PDGFB@ZIF8‐RGD) is proposed. PDGFB@ZIF8‐RGD can facilitate trafficking and infiltration of immune effector cells by inducing tumor vascular normalization and trigger effector cell immune activation, thereby reprogramming the TIME from “cold” to “hot”, initiating robust antitumor immunity and suppressing tumor growth.